Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history

Ratios

vs
industry
vs
history
P/E(ttm) 20.26
FVD's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 20.26 )
Ranked among companies with meaningful P/E(ttm) only.
FVD' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 21.52
Current: 20.26
0
21.52
PE(NRI) 20.26
FVD's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 20.26 )
Ranked among companies with meaningful PE(NRI) only.
FVD' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 21.52
Current: 20.26
0
21.52
P/B 2.55
FVD's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 2.55 )
Ranked among companies with meaningful P/B only.
FVD' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.67
Current: 2.55
0
2.67

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.03
FVD's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 2.03 )
Ranked among companies with meaningful Dividend Yield only.
FVD' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.16
Current: 2.03
0
2.16
Yield on cost (5-Year) 2.03
FVD's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 2.03 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
FVD' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.16
Current: 2.03
0
2.16

More Statistics

Short Percentage of Float0.00%
52-Week Range $22.35 - 27.75
Shares Outstanding (Mil)97,587,986.00
» More Articles for FVD

Headlines

Articles On GuruFocus.com
Low-Priced Retail Stocks Gurus Shopped for Ahead of Holiday Season Dec 02 2016 
Barrick Repurchases $595 Million of Corporate Loan Dec 02 2016 
23 Questions With Bakul Lalla Dec 02 2016 
Qualcomm: Balance Sheet, Dividend Yield Make It Attractive Dec 02 2016 
Apple: A Dividend Achiever in the Making Dec 02 2016 
Neiman Marcus Debenture Bonds Yielding 8% Dec 02 2016 
Competitor Performance Is Eating Nike’s Lunch Dec 02 2016 
Smith & Wesson Reports Strong Quarter, but Stock Suffers Post Election Dec 02 2016 
6 Things That May Surprise You About Building Wealth Dec 02 2016 
Carl Icahn Takes 15% Stake in Enzon Pharmaceuticals Dec 02 2016 

More From Other Websites
Teva’s Research Pipeline to Culminate in Many New Drug Launches? Nov 24 2016
The Latest on Fasinumab, a Teva-Regeneron Collaborative Drug Nov 22 2016
Teva Pharmaceutical Expects Mid-Single-Digit Growth for Generics Nov 21 2016
Performance of Novartis’s Innovative Medicines Segment in 3Q16 Nov 17 2016
Changes in Novartis’s Valuation for 3Q16 Nov 16 2016
Bernstein: Excess Risk Aversion Has Made Investors ‘Wallflowers’ Nov 16 2016
Inside AstraZeneca’s Oncology Segment Growth in 3Q15 Nov 15 2016
Inside AstraZeneca’s Revenue Fall in 3Q16 Nov 11 2016
Richard Bernstein: Don’t Fear the Bear Market Oct 24 2016
Volume Growth and Product Mix to Drive NVO’s Insulin Sales Oct 03 2016
Can Novo Nordisk Continue to Maintain Market Share in Modern Insulin? Oct 03 2016
Diabetes Care Market Expected to Offer Strong Growth for Novo Nordisk Sep 29 2016
A Look at Teva’s Dominance in the Biosimilar Space Sep 28 2016
Teva Pharmaceutical Leads in Global Generic Pharmaceutical Space Sep 26 2016
First Trust Advisors L.P. Announces Distributions for Exchange-Traded Funds Sep 20 2016
Analyst Price Targets and Recommendations for Sanofi Sep 16 2016
USMV vs. FVD: Comparing Smart Beta Funds Sep 16 2016
Sanofi’s Rare Disease Franchise Continues to Be a Revenue Boon Sep 15 2016
How Sanofi’s Various Franchises Performed in 2Q16 Sep 14 2016
How Sanofi’s Franchises Could Perform into 2017 Sep 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK